Dr. Karan Dixit
Claim this profileNorthwestern University
Studies Glioblastoma
Studies Relapse
5 reported clinical trials
11 drugs studied
Area of expertise
1Glioblastoma
IDH negative
MET negative
2Relapse
IDH negative
Affiliated Hospitals
Clinical Trials Karan Dixit is currently running
Ultrasound-assisted Chemotherapy
for Glioblastoma
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the blood-brain barrier (BBB). In this trial we will implant a novel device with 9 ultrasound emitters allowing to temporarily and reversibly open the BBB immediately prior to chemotherapy infusion with albumin-bound paclitaxel. In the phase 1 component, increasing doses of chemotherapy will be delivered as long deemed safe based on the prior patient not experiencing severe toxicity. Once the the recommended dosing has been established, carboplatin will be added to the regimen and additional patients will be treated in order to better evaluate the antitumor efficacy of this novel treatment. The device will be implanted at the time of surgical resection of the recurrent tumor. During that procedure and when feasible, a first test dose of the chemotherapy will be administered in the operating room after sonication (procedure of activating ultrasound and opening the BBB) and tissue concentrations in different parts of the resected tumor will be measured. In select patients, the sonication procedure may occur immediately after the test dose of chemotherapy is administered. The objectives of this trial are to establish a safe and effective dose of albumin-bound paclitaxel, to demonstrate that the opening of the BBB increases chemotherapy concentration in the tumor, and to estimate how effective this treatment is in reducing the tumor burden and prolonging life.
Recruiting3 awards Phase 1 & 219 criteria
Rhenium-186 NanoLiposome
for Leptomeningeal Metastasis
This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).
Recruiting1 award Phase 19 criteria
More about Karan Dixit
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Karan Dixit has experience with
- Temozolomide
- Triapine
- Ipilimumab
- Nivolumab
- Radiation Therapy
- Carboplatin
Breakdown of trials Karan Dixit has run
Glioblastoma
Relapse
Gliomas
Brain Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Karan Dixit specialize in?
Karan Dixit focuses on Glioblastoma and Relapse. In particular, much of their work with Glioblastoma has involved IDH negative patients, or patients who are MET negative.
Is Karan Dixit currently recruiting for clinical trials?
Yes, Karan Dixit is currently recruiting for 3 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Karan Dixit has studied deeply?
Yes, Karan Dixit has studied treatments such as Temozolomide, Triapine, Ipilimumab.
What is the best way to schedule an appointment with Karan Dixit?
Apply for one of the trials that Karan Dixit is conducting.
What is the office address of Karan Dixit?
The office of Karan Dixit is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.